PPV without ILM peeling favourable for ODP

Article

Pars plana vitrectomy, endolaser photocoagulation and C3F8 gas tamponade without internal limiting membrane (ILM) peeling have been found to be potentially favourable in the treatment of optic disc pit (ODP) maculopathy, according to data published in Eye.

Pars plana vitrectomy, endolaser photocoagulation and C3F8 gas tamponade without internal limiting membrane (ILM) peeling have been found to be potentially favourable in the treatment of optic disc pit (ODP) maculopathy, according to data published in Eye.

Dr R. Avci et al. (Retina Eye Hospital, Bursa, Turkey) examined 13 eyes from 12 patients undergoing surgery to treat serous macular detatchment and/or macular retinoschisis secondary to congenital ODP. All patients included in the study were treated with PPV, posterior hyaloid removal, endolaser photocoagulation on the temporal margin of the optic disc and 12% C3F8 gas tamponade.

The team used optical coherence tomography (OCT) to analyse the anatomic success and functional outcome of surgery and they measured the patients’ best-corrected visual acuity (BCVA) as well. The majority of the study group experienced an improvement in BCVA of 2 lines or more and 12 eyes experienced complete reabsorption or subretinal and intraretinal fluid.

These results indicated that PPV, C3F8 gas tamponade and endolaser to the optic disc margin without ILM peeling could be a beneficial surgical option for patients suffering with ODP maculopathy and earlier surgical intervention leads to better visual improvements.

For further information please view the abstract here.

Newsletter

Join ophthalmologists across Europe—sign up for exclusive updates and innovations in surgical techniques and clinical care.

Recent Videos
A photo of Seville, Spain, with the Congress on Controversies in Ophthalmology logo superimposed on it. Image credit: ©francovolpato – stock.adobe.com; logo courtesy COPHy
Anat Loewenstein, MD, Professor and Director, Department of Ophthalmology, Tel Aviv Medical Center, discusses the Congress on Controversies in Ophthalmology (COPHy)
Anat Loewenstein, MD, speaks about the 22nd Annual Angiogenesis, Exudation, and Degeneration Meeting in February 2025 and shares her global forecast for AI-driven home OCT
Sarah M. Thomasy, DVM, PhD, DACVO, a veterinary ophthalmologist at UC Davis, talks about how her research at the Glaucoma 360 symposium
I. Paul Singh, MD, an anterior segment and glaucoma specialist, discusses the Glaucoma 360 conference, where he participated in a panel discussion on the use of artificial intelligence (AI) in glaucoma care.
Charles Wykoff, MD, PhD, discusses his Floretina ICOOR presentation topic, retinal non-perfusion in diabetic retinopathy, with David Hutton, editor of Ophthalmology Times
Elizabeth Cohen, MD, discusses the Zoster Eye Disease study at the 2024 AAO meeting
Victoria L Tseng, MD, PhD, professor of ophthalmology and glaucoma specialist, UCLA
© 2025 MJH Life Sciences

All rights reserved.